In female patients living with sickle cell disease (SCD), hydroxyurea had no effect on ovarian reserve, suggesting that fertility preservation measures prior to treatment may be unnecessary, according to a study published in Blood Advances.
ASCO24: Another win for Opdivo/Yervoy in first-line HCC despite uncertainties – Pharmaceutical Technology
Data with Bristol Myers Squibb’s Opdivo/Yervoy combination in frontline hepatocellular carcinoma were recently presented at the American Society of Clinical Oncology (ASCO) 2024 Annual meeting.